International Journal of Hematology

, Volume 86, Issue 1, pp 84–90 | Cite as

Study of Relieving Graft-versus-Host Disease by Blocking CD137-CD137 Ligand Costimulatory Pathway in Vitro



Engagement of the TCR without appropriate costimulation will result in the inability of T-cells to respond to the alloantigen as described earlier. We made a further investigation into the effect of relieving graft-versus-host disease (GVHD) and its mechanism in mice by blocking CD137-CD137L pathway in vitro. Responder cells (spleen cells) from BALB/C donor mice (H-2d) were incubated with stimulator cells (spleen cells) from C57BL/6 recipient mice (H-2b),with or without anti-CD137L monoclonal antibodies (MoAbs). Donor bone marrow cells plus mixed lymphocyte culture (MLC) T-cells were transplanted into lethally irradiated C57BL/6 mice. C57BL/6 mice were divided into 3 groups: group A (allogeneic bone marrow transplantation control group), group B (cyclosporine + methotrexate group), and group C (donor T-cells were treated with anti-CD137L MoAbs). The percentage of CD3+CD4+ and CD3+CD8+ T-cells were detected by flow cytometry, and the levels of cytokines (IFN-γ, interleukin [IL]-2, IL-10, IL-4) by reverse-transcriptase polymerase chain reaction.The incidence of GVHD in group C was 70%, while the incidence of GVHD was 100% in group A and group B. The survival rate of group C was higher than that of group A and B, and the median survival time was longer than that of group A and B(P < .01). Clinical symptoms and histological signs of GVHD in group C were the mildest among all 3 groups. The percentage of CD3+CD8+ T-cells in group C was lower than that in group A and B(P < .01). The levels of IFN-γ in group C were markedly lower than those in group A and B(P < .01), and the levels of IL-10 in group C were significantly higher than those in group A and B(P < .01).The results suggest that treatment of donor T-cells by anti-CD137L MoAbs in vitro may relieve GVHD, thereby improve the survival time and survival rate of recipient mice, which might be related to the increased TH1 cytokine (IFN-γ) and decreased TH2 cytokine (IL-10) as well as the reduced CD3+CD8+ T-cells.

Key words

Bone marrow transplantation Graft-versus-host disease Anti-CD137L MoAbs Immune tolerance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors a nationwide survey conducted in Japan.Bone Marrow Transplant. 2004; 34:331–337.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee SJ, Klein SP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.Blood. 2002;100:406–414.CrossRefPubMedGoogle Scholar
  3. 3.
    Socie G, Loiseau P,Tamouza R, et al. Both genetic and clinical factor predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Transplantation. 2001;72:699–706.CrossRefPubMedGoogle Scholar
  4. 4.
    Goodwin RG, Din WS, Davis-Smith T, et al. Molecular cloning of a ligand for the inducible T cell gene 4–1BB:a member of an emerging family of cytokines with homology to tumor necrosis factor.Eur J Immunol. 1993;23:2631–2641.CrossRefPubMedGoogle Scholar
  5. 5.
    Schrwarz H, Valbracht J, Tuckwell J, et al. ILA, the human 4–1BB homologue, is inducible in lymphoid and other cell lineages.Blood. 1995;85:1043–1052.Google Scholar
  6. 6.
    Hurtado J, Kim K, Pollok,et al. Potential role of 4–1BB in T cell activation: comparison with the costimulatory molecule CD28.J Immunol. 1995;155:3360–3367.PubMedGoogle Scholar
  7. 7.
    Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+T lymphocytes by increasing expression of Bcl-xL and Bfl-l.J Immunol. 2002;169:4882–4888.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee HW, Nam KD, Seo SK, et al. 4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes.Cell Immunol. 2003;223:143–150.CrossRefPubMedGoogle Scholar
  9. 9.
    Tan JT, Ha J, Cho HR, et al. Analysis of expression and function of the costimulatory molecule 4–1BB in alloimmune responses.Transplantation. 2000;70:175–183.PubMedGoogle Scholar
  10. 10.
    Ketheesan N, Hirst RG. Cytokine gene expression in innately susceptible BALB/C mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.Infect Immun. 2000;68:2034–2042.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schonrich G, Kalinke U, Momburg F, et al. Down-regulation of cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction.Cell. 1991;65:293–304.CrossRefPubMedGoogle Scholar
  12. 12.
    Markees TG, Nancy EP, Randolph JN, et al. Ponged survival of mouse skin allograft and antibody to CD40 ligand.Transplantation. 1997;64:329–335.CrossRefPubMedGoogle Scholar
  13. 13.
    Ferrara JL, Levg R, Chao NJ. Pathophysiologic mechanisms of acute graft-versus-host disease.Bid Blood Marrow Transplant. 1999;5:347–356.CrossRefGoogle Scholar
  14. 14.
    Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.N Engl J Med. 1998;339:1186–1193.CrossRefPubMedGoogle Scholar
  15. 15.
    Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.Blood. 1999;94:2192–2199.PubMedGoogle Scholar
  16. 16.
    Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft versus host disease in patients given HLA-identical marrow grafts for leukemia: long term follow up of a controlled trial.Blood. 1989;73:1729–1734.PubMedGoogle Scholar
  17. 17.
    Nozawa K, Ohata J, Sakurai J, et al. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.J Immunol. 2001;167:4981–4986.CrossRefPubMedGoogle Scholar
  18. 18.
    Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4–1BB. Analysis of expression and function.J Immunol. 1993;150:771–781.PubMedGoogle Scholar
  19. 19.
    Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.J Immunol. 2001;167:1313–1324.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim YJ, Mantel PL, June CH, et al. 4-1BB costimulation promotes human T cell adhesion to fibronectin.Cell Immunol. 1999; 192:13–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Tan JT, Whitmire JK, Ahmed R. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.J Immunol. 1999;163:4859–4868.PubMedGoogle Scholar
  22. 22.
    Myers L, Takahashi C, Mittler RS, et al. Effector CD8 T cells possess suppressor function after 4–1BB and Toll-like receptor triggering.Proc Natl Acad Sci U S A. 2003;100:5348–5354.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol. 1986;136:2348–2357.PubMedGoogle Scholar
  24. 24.
    Jadus MR, Peck AB. Lethal murine graft-versus-host disease in the absence of detectable cytoxic T lymphocytes.Transplantation. 1983;36:281–289.CrossRefPubMedGoogle Scholar
  25. 25.
    Malkovsky M, Brenner MK, Hunt R, et al. T cell-depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin-2.Cell Immunol. 1986; 103:476–480.CrossRefPubMedGoogle Scholar
  26. 26.
    Szebeni J, Wang MG, Pearson DA, et al. IL-2 inhibits early increases in serum γ-interferon levels associated with graft-versus-host-disease.Transplantation. 1994;58:1385–1393.PubMedGoogle Scholar
  27. 27.
    Wang MG, Szebeni J, Pearson DA, et al. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4 + helper cells.Transplantation. 1995;60:481–490.CrossRefPubMedGoogle Scholar
  28. 28.
    Velardi A, Vareae P, Terenzi A, et al. Lymphokine production by T-cell clones after human bone marrow transplantation.Blood. 1989;74:1665–1672.PubMedGoogle Scholar
  29. 29.
    Zeller JC, Panoskaltisis-Mortari A, Murphy WJ, et al. Induction of CD4 + T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-β.J Immunol. 1999;163:3684–3691.PubMedGoogle Scholar
  30. 30.
    Boussiotis VA, Chen ZM, Zeller JC, et al. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease.Blood. 2001;97:565–571.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  1. 1.Department of HematologyAffiliated Hospital of Xuzhou Medical CollegeJiangsuP. R. China

Personalised recommendations